Finerenone is at least as effective in patients who are in the hospital or were recently hospitalized for heart failure as those with stable condition, said Akshay Desai, MD, of Brigham & Women’s ...
Phoenix researcher was recently awarded a $1.9 million National Institutes of Health grant to study the molecular mechanisms of how dilated cardiomyopathy progresses to heart failure, which could ...
A new analysis from SEQUOIA-HCM showed that treatment with aficamten was associated with beneficial changes in five indices reflecting structural, electrophysiologic and biomarker changes in patients ...
Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population Study design intended to ...
Cardiomyopathy occurred in 3.8% of the 1813 TAGRISSO-treated patients ... including assessment of LVEF at baseline and during treatment. For patients receiving TAGRISSO in combination with pemetrexed ...
Standard ALL treatment usually takes between 2 to 3 years. The maintenance phase takes up most of this time as it lasts 2 years. During the maintenance phase people often go back to work or college.